Albumin Based Iohexol Nanoparticles for Computed Tomography: An In Vivo Study

Abstract

Iohexol is a commonly used second generation non-ionic iodinated contrast agent with a multitude of advantages such as low osmolarity and competent intravenous countenance having minimum adverse reactions. Our study anticipated to improve the efficacy of Iohexol as a contrast enhancing agent for Computed Tomography, by envisaging bio-compatible albumin based Iohexol nanoparticles. This nanoparticulate system was developed primarily to enhance the anatomic imaging while increasing its residence time in the blood pool. Towards this goal, we developed Iohexol albumin nanoparticles using glutaraldehyde as a cross linking agent, and Polyethylene glyocol Iohexol albumin nanoparticles by physical adsorption to ameliorate its circulation time. These formulations were studied in comparison to the clinically available Iopamidol™. Both Iohexol albumin nanoparticles and Polyethylene glyocol Iohexol albumin nanoparticles were characterized for its size, physicochemical properties and entrapment efficiency. Iohexol albumin nanoparticles showed a size range of 254±5 nm and post surface modification the size of Polyethylene glyocol Iohexol albumin nanoparticles was found to be 283±7 nm in diameter, with and entrapment efficiency Iohexol as of 85%. Further, In vivo computed tomography imaging in New Zealand white rabbits for the developed formulations manifested an enhancement in the anatomical structures of heart, liver and kidneys along with an increased residence time in the blood pool of 3 h in contrast to Iopamidol™. Our study interprets that Polyethylene glyocol Iohexol albumin nanoparticles have prolonged residence time producing much greater conspicuity of anatomic features and warrants further detail study of the formulation in disease models.